1. Pink Sheet
  2. >>Advanced Technologies
  3. >>Digital Technologies

Artificial Intelligence Legislative Activity To Start In Fall; Sen. Schumer Lays Out Principles, Process

 
• By Ramsey Baghdadi

As US FDA offers initial issues for industry consideration, Senate majority leader outlines framework and process of a bipartisan effort to construct the ‘first of its kind’ legislation to regulate AI.

robot writing legislation
• Source: Shutterstock

Any industry wondering how the US government will regulate artificial intelligence should start paying attention in the fall.

That’s when the Senate will introduce “a new legislative approach” of “AI insight forums” that will inform landmark legislation in the near future.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Digital Technologies

More from Advanced Technologies

Keep Talking: US FDA’s Beleaguered Biologics Center Remains Vital To Regenerative Medicine

 
• By Bridget Silverman

Advisory committee for Capricor’s deriamocel planned, regenerative medicine advanced therapy designations proliferate for osteoarthritis, and the ranks of dual RMAT/breakthrough therapy designation holders grow.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.

EU Wants Industry To Define ‘Trade Secrets’ Under Health Data Sharing Regulation

 
• By Eliza Slawther

The European Health Data Space Regulation is deliberately “vague” when it comes to defining trade secrets because the EU wants the pharma industry to make recommendations on safeguarding intellectual property, a policy officer for the European Commission says.